Shilpa Medicare Limited AI Stock Analysis
Want to see IN:SHILPAMED full AI Analyst Report?
Shilpa Medicare Limited (SHILPAMED) AI Stock Analysis
Shilpa Medicare Limited
(NSE:SHILPAMED)
The overall score reflects a company in a solid recovery phase: revenues and profits are growing with improving margins and moderate leverage, which is the primary driver of the rating. Strong technical momentum and a clear uptrend further support the score, signaling positive market sentiment. However, the rich valuation and history of negative free cash flow temper the upside, keeping the stock in an attractive but not top‑tier range.
Shilpa Medicare Limited (SHILPAMED) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 181.28B
- Dividend Yield
- 0.07%
- Average Volume (3M)
- 64.95K
- Price to Earnings (P/E)
- 54.1
- Beta (1Y)
- 0.47
- Revenue Growth
- 37.27%
- EPS Growth
- 142.29%
- Country
- India
- Employees
- 1,132
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Shilpa Medicare Limited Business Overview & Revenue Model
Company Description
Shilpa Medicare Limited, including its various subsidiaries, manufactures and distributes a range of active pharmaceutical ingredients (APIs), intermediate compounds, and finished drug formulations. Operating across India, the United States, Europe,...
Shilpa Medicare Limited Financial Statement Overview
Summary
Financial performance is strong overall, with steady multi‑year revenue growth, sharply improved profitability after a loss in 2023, and moderate leverage supported by a solid equity base, but persistently weak free cash flow and past margin volatility prevent a top‑tier score.
Income Statement
82Very PositiveBalance Sheet
78PositiveCash Flow
55Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.42B | 15.39B | 12.86B | 11.53B | 10.43B | 11.40B |
| Gross Profit | 10.11B | 6.24B | 8.76B | 7.10B | 1.34B | 7.56B |
| EBITDA | 5.18B | 4.35B | 3.11B | 2.46B | 1.13B | 2.23B |
| Net Income | 3.32B | 2.43B | 782.93M | 318.74M | -325.33M | 606.62M |
Balance Sheet | ||||||
| Total Assets | 41.38B | 37.06B | 33.11B | 30.93B | 29.04B | 28.75B |
| Cash, Cash Equivalents and Short-Term Investments | 1.11B | 451.80M | 585.61M | 302.26M | 221.92M | 338.29M |
| Total Debt | 6.66B | 6.60B | 5.88B | 9.37B | 7.98B | 6.83B |
| Total Liabilities | 13.80B | 11.14B | 9.47B | 12.93B | 11.30B | 10.64B |
| Stockholders Equity | 27.58B | 25.91B | 23.72B | 18.09B | 17.83B | 18.22B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -754.00M | -1.11B | -492.22M | -467.44M | -2.27B |
| Operating Cash Flow | 0 | 2.95B | 1.32B | 1.35B | 1.80B | 1.05B |
| Investing Cash Flow | 0 | -3.27B | -1.99B | -1.67B | -2.33B | -2.85B |
| Financing Cash Flow | 0 | 612.20M | 626.54M | 467.75M | 457.98M | 828.58M |
Shilpa Medicare Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SHILPAMED, the sentiment is Negative. The current price of 917.00 is below the 20-day moving average (MA) of 921.32, below the 50-day MA of 966.18, and above the 200-day MA of 618.75, indicating a neutral trend. The MACD of -0.67 indicates Negative momentum. The RSI at 45.43 is Neutral, neither overbought nor oversold. The STOCH value of 49.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SHILPAMED.
Shilpa Medicare Limited Peers Comparison
Overall Rating
IN:STAR77Outperform
IN:CAPLIPOINT75Outperform
IN:AKUMS73Outperform
IN:SHILPAMED71.4Outperform
IN:APLLTD71Outperform
IN:JUBLPHARMA49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | INR 90.65B | 14.68 | ― | 0.51% | 11.28% | 55.18% | |
| 75Outperform | INR 171.11B | 24.79 | ― | 0.36% | 16.84% | 17.02% | |
| 73Outperform | INR 112.80B | 30.16 | ― | 0.42% | 17.50% | 14.74% | |
| 71Outperform | INR 179.35B | 54.08 | ― | 0.07% | 37.27% | 142.29% | |
| 71Outperform | INR 206.50B | 24.48 | ― | 1.14% | 19.68% | 33.03% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 49Neutral | INR 151.92B | 57.43 | ― | 0.52% | 18.30% | -44.95% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:SHILPAMED | Shilpa Medicare Limited | 917.00 | 555.43 | 153.61% | |
| IN:AKUMS | Akums Drugs and Pharmaceuticals Limited | 716.65 | 294.10 | 69.60% | |
| IN:APLLTD | Alembic Pharmaceuticals Limited | 1050.55 | 157.54 | 17.64% | |
| IN:CAPLIPOINT | Caplin Point Laboratories Limited | 2251.10 | 327.98 | 17.05% | |
| IN:JUBLPHARMA | Jubilant Pharmova Limited | 953.80 | -148.44 | -13.47% | |
| IN:STAR | Strides Pharma Science Ltd | 983.45 | 26.73 | 2.79% |
Shilpa Medicare Limited Corporate Events
Shilpa Medicare’s Jadcherla Unit Wins European GMP Nod
Shilpa Medicare Limited operates in the pharmaceutical industry, focusing on the manufacturing, testing and distribution of sterile injections and non-sterile tablet and capsule finished dosage forms. From its Unit 4 facility in Jadcherla, Telangana,...
Shilpa Medicare’s 39th AGM Confirms Clean Audit and Reviews Outlook
Shilpa Medicare Limited convened its 39th Annual General Meeting on September 11, 2026, via video conferencing and other audio-visual means from its registered office, adhering to guidelines issued by the Ministry of Corporate Affairs and SEBI. The m...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 19, 2026
